Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
Ten patients received two doses of Rabavert; Case reference number US-BN-2025-001594 is a spontaneous case initially received from other health professional via agency (reference number: USBAV25-2370) on 16-Sep-2025 and concerns 10 patients of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On an unspecified date, on day one, the ten patients received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration for the indication pre-exposure prophylaxis. On an unspecified date, on day seven, the patient received the second dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route or site of administration and no third vaccine as recommended per manufacturer (explicitly coded as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patients experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns 10 patients of unspecified age and gender, had received RabAvert vaccine for an indication of pre-exposure prophylaxis. As reported, there was no third dose administered, which is considered as incomplete course of vaccination. At the time of the initial report, it was unknown if the patients experienced any adverse events due to RabAvert. Incomplete course of vaccination is considered as listed as per company convention. The patient's medical history and concomitant medication details were not provided. Event incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns 10 patients of unspecified age and gender, had received RabAvert vaccine for an indication of pre-exposure prophylaxis. As reported, there was no third dose administered, which is considered as incomplete course of vaccination. At the time of the initial report, it was unknown if the patients experienced any adverse events due to RabAvert. Incomplete course of vaccination is considered as listed as per company convention. The patient's medical history and concomitant medication details were not provided. Event incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None